MLP Saglik Hizmetleri (MPARK) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
17 Aug, 2026Executive summary
Revenue for the six months ended June 30, 2026, reached TRY 34,127,444, up from TRY 32,143,591 year-over-year.
Net profit attributable to equity holders was TRY 3,153,018, compared to TRY 3,018,030 in the prior year period.
Total assets stood at TRY 95,303,606 as of June 30, 2026, with equity attributable to owners at TRY 43,827,509.
The group operates 18 subsidiaries in the healthcare sector, with 14,635 employees as of June 30, 2026.
Financial highlights
Gross profit for the six-month period was TRY 8,929,943, up from TRY 8,560,715 year-over-year.
Operating profit reached TRY 5,200,867, down from TRY 5,914,793 in the prior year period.
EBITDA and EBIT not explicitly stated, but depreciation and amortization expenses totaled TRY 1,879,904 in cost of service and TRY 98,501 in admin expenses.
Basic earnings per share for the period was 16.51, compared to 15.80 in the prior year.
Cash and cash equivalents at period end were TRY 8,255,897, down from TRY 9,468,876 at year-end 2025.
Outlook and guidance
No explicit forward-looking guidance provided, but the group continues to invest in property, plant, and equipment, and maintains a strong capital base.
Latest events from MLP Saglik Hizmetleri
- Revenue and EBITDA rose, but free cash flow and cash balances declined amid inflationary pressures.MPARK
Q1 2026 - Revenue up 6%, EBITDA up 14.8%, net profit down 18.8% amid expansion and acquisitions.MPARK
Q4 2025 - Revenue and EBITDA rose, but net profit fell as expansion and acquisitions drove costs higher.MPARK
Q3 2025 - Revenue and EBITDA rose, but net profit fell as costs, borrowings, and capex surged.MPARK
Q2 2025 - Revenue and EBITDA up 22% year-over-year, with improved leverage and strong cash flow.MPARK
Q4 2024 - Strong revenue and profit growth fueled by insurance, acquisitions, and international expansion.MPARK
Q3 2024 - Revenue and EBITDA surged in H1 2024, fueled by insurance, expansion, and acquisitions.MPARK
Q2 2024 - Revenue and profit surged, but higher capex and inflation risks impacted cash flow.MPARK
Q1 2025